Therapeutic Approach for Metastatic Renal Cell Carcinoma
Therapeutic Approach for Metastatic Renal Cell Carcinoma
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
- A 73-year old woman with clear cell RCC, hyperlipidemia, and type 2 diabetes, which are both managed medically
- Her baseline patient and disease characteristics were:
- ECOG PS 0, KPS 90
- pT3bNxM0 (AJCC stage 3)
- 5-cm left kidney tumor mass with extension into the left renal vein
- She underwent radical nephrectomy within 1 month following diagnosis
December 2017
- The patient reported loss of appetite and weight loss
- CT imaging showed multiple liver lesions, 2 small nodules in the right lung upper lobe, and mediastinal lymphadenopathy
- Laboratory findings notable for Ca2+ 14.8 mg/dL
- PD-L1 expression, <1%
- Remarks: RCC disease progression; IMDC risk stratification, intermediate
- The patient was started on cabozantinib, 60 mg daily
- After 4 weeks on therapy she developed grade 2 diarrhea and her dose was reduced to 40 mg
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
